161 related articles for article (PubMed ID: 37791067)
41. Lenvatinib plus transarterial chemoembolization with or without immune checkpoint inhibitors for unresectable hepatocellular carcinoma: A review.
Sun L; Xu X; Meng F; Liu Q; Wang H; Li X; Li G; Chen F
Front Oncol; 2022; 12():980214. PubMed ID: 36249023
[TBL] [Abstract][Full Text] [Related]
42. Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: A biomolecular exploratory, phase II trial.
Lai Z; He M; Bu X; Xu Y; Huang Y; Wen D; Li Q; Xu L; Zhang Y; Wei W; Chen M; Kan A; Shi M
Eur J Cancer; 2022 Oct; 174():68-77. PubMed ID: 35981413
[TBL] [Abstract][Full Text] [Related]
43. Case report: Conversion therapy to permit resection of initially unresectable hepatocellular carcinoma.
Chen K; Luo CP; Ge DX; Wang KL; Luo Q; Li YZ; You XM; Xiang BD; Li LQ; Ma L; Zhong JH
Front Oncol; 2022; 12():946693. PubMed ID: 36276151
[TBL] [Abstract][Full Text] [Related]
44. Sorafenib combined with embolization plus hepatic arterial infusion chemotherapy for inoperable hepatocellular carcinoma.
Liu BJ; Gao S; Zhu X; Guo JH; Zhang X; Chen H; Wang XD; Yang RJ
World J Gastrointest Oncol; 2020 Jun; 12(6):663-676. PubMed ID: 32699581
[TBL] [Abstract][Full Text] [Related]
45. Safety and efficacy of radiotherapy combined with lenvatinib plus PD-1 inhibitors as neo-adjuvant therapy in hepatocellular carcinoma with portal vein thrombus: protocol of an open-label, single-arm, prospective, multi-center phase I trial.
Li G; Shu B; Zheng Z; Yin H; Zhang C; Xiao Y; Yang Y; Yan Z; Zhang X; Yang S; Li G; Dong J
Front Oncol; 2022; 12():1051916. PubMed ID: 36505833
[TBL] [Abstract][Full Text] [Related]
46. Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and sequential ablation in the treatment of advanced hepatocellular carcinoma.
Liu Y; Qiao Y; Zhou M; Guo J; Lin Y; Li W; An C; Li C
Cancer Med; 2023 Mar; 12(5):5436-5449. PubMed ID: 36254376
[TBL] [Abstract][Full Text] [Related]
47. Efficacy of hepatic arterial infusion chemotherapy in combination with irradiation for advanced hepatocellular carcinoma with portal vein invasion.
Onishi H; Nouso K; Nakamura S; Katsui K; Wada N; Morimoto Y; Miyahara K; Takeuchi Y; Kuwaki K; Yasunaka T; Miyake Y; Shiraha H; Takaki A; Kobayashi Y; Sakaguchi K; Kanazawa S; Yamamoto K
Hepatol Int; 2015 Jan; 9(1):105-12. PubMed ID: 25788384
[TBL] [Abstract][Full Text] [Related]
48. Triplet regimen as a novel modality for advanced unresectable hepatocellular carcinoma: A case report and review of literature.
Zhao Y; He GS; Li G
World J Clin Cases; 2023 Sep; 11(27):6558-6564. PubMed ID: 37900216
[TBL] [Abstract][Full Text] [Related]
49. Hepatic arterial infusion chemotherapy plus lenvatinib with or without programmed cell death protein-1 inhibitors for advanced cholangiocarcinoma.
Wei Z; Wang Y; Wu B; Liu Y; Wang Y; Ren Z; Yang X; Chen Q; Zhang Y
Front Immunol; 2023; 14():1235724. PubMed ID: 37720223
[TBL] [Abstract][Full Text] [Related]
50. Hepatic arterial infusion chemotherapy combined with anti-PD-1/PD-L1 immunotherapy and molecularly targeted agents for advanced hepatocellular carcinoma: a real world study.
Zhang W; Zhang K; Liu C; Gao W; Si T; Zou Q; Guo Z; Yang X; Li M; Liu D; Mu H; Li H; Yu H; Xing W
Front Immunol; 2023; 14():1127349. PubMed ID: 37180098
[TBL] [Abstract][Full Text] [Related]
51. Downstaging and Conversation Strategy for Advanced Hepatocellular Carcinoma with Portal Vein Branch Tumor Thrombus: TACE,
Zhao XH; Li HL; Guo CY; Yao QJ; Xia WL; Hu HT
J Hepatocell Carcinoma; 2023; 10():231-240. PubMed ID: 36819987
[TBL] [Abstract][Full Text] [Related]
52. [Comparison of therapeutics effects of transcatheter arterial chemoembolization combined with iodine-125 seed implantation and sorafenib for the treatment of hepatocellular carcinoma with portal vein tumor thrombosis].
Luo J; Zheng JP; Shao GL; Wen S; Guo LW; Zeng H; Zhang L; Qian CY; Hao WY
Zhonghua Gan Zang Bing Za Zhi; 2018 Apr; 26(4):298-304. PubMed ID: 29996343
[No Abstract] [Full Text] [Related]
53. Comparison of Sorafenib versus Hepatic Arterial Infusion Chemotherapy-Based Treatment for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis.
Ahn YE; Suh SJ; Yim HJ; Seo YS; Yoon EL; Kim TH; Lee YS; Yim SY; Kim HR; Kang SH; Jung YK; Kim JH; Yeon JE; Um SH; Byun KS
Gut Liver; 2021 Mar; 15(2):284-294. PubMed ID: 32307975
[TBL] [Abstract][Full Text] [Related]
54. Hepatic arterial infusion of oxaliplatin plus raltitrexed in unresectable hepatocellular carcinoma with or without portal vein tumour thrombosis.
Chen S; Yu W; Zhang K; Liu W; Wang X; Chen C
Gastroenterol Rep (Oxf); 2022; 10():goac016. PubMed ID: 35582475
[TBL] [Abstract][Full Text] [Related]
55. Radiotherapy plus transarterial chemoembolization for hepatocellular carcinoma invading the portal vein: long-term patient outcomes.
Yoon SM; Lim YS; Won HJ; Kim JH; Kim KM; Lee HC; Chung YH; Lee YS; Lee SG; Park JH; Suh DJ
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):2004-11. PubMed ID: 21621346
[TBL] [Abstract][Full Text] [Related]
56. Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy
He MK; Liang RB; Zhao Y; Xu YJ; Chen HW; Zhou YM; Lai ZC; Xu L; Wei W; Zhang YJ; Chen MS; Guo RP; Li QJ; Shi M
Ther Adv Med Oncol; 2021; 13():17588359211002720. PubMed ID: 33854567
[TBL] [Abstract][Full Text] [Related]
57. Safety and efficacy of lenvatinib combined with camrelizumab plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: A two-center retrospective study.
Sun B; Zhang L; Sun T; Ren Y; Cao Y; Zhang W; Zhu L; Guo Y; Gui Y; Liu F; Chen L; Xiong F; Zheng C
Front Oncol; 2022; 12():982948. PubMed ID: 36172158
[TBL] [Abstract][Full Text] [Related]
58. Controlling Major Portal Vein Invasion Progression during Lenvatinib Treatment by Carbon-Ion Radiotherapy in Patients with Advanced Hepatocellular Carcinoma.
Yoshida R; Koroki K; Makishima H; Ogasawara S; Ishino T; Ogawa K; Nakagawa M; Fujiwara K; Unozawa H; Iwanaga T; Fujita N; Sakuma T; Kanzaki H; Kobayashi K; Kanogawa N; Kiyono S; Nakamura M; Kondo T; Saito T; Nakagawa R; Suzuki E; Ooka Y; Nakamoto S; Tawada A; Chiba T; Arai M; Kaneko T; Wakatsuki M; Kato J; Tsuji H; Kato N
Case Rep Oncol; 2021; 14(2):1103-1110. PubMed ID: 38075390
[TBL] [Abstract][Full Text] [Related]
59. Sorafenib Plus Hepatic Arterial Infusion Chemotherapy versus Sorafenib for Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis: A Randomized Trial.
Zheng K; Zhu X; Fu S; Cao G; Li WQ; Xu L; Chen H; Wu D; Yang R; Wang K; Liu W; Wang H; Bao Q; Liu M; Hao C; Shen L; Xing B; Wang X
Radiology; 2022 May; 303(2):455-464. PubMed ID: 35103539
[TBL] [Abstract][Full Text] [Related]
60. Case report: Primary hepatocellular carcinoma with portal vein tumor thrombus characterized by active tumor immune microenvironment achieving a complete response following treatment of combined immunotherapy.
Zhong K; Xu Y; Cheng Y; Wen Y; Cai L; He G; Huang H; Fu S; Zhong X; Zheng Y; Chen T; Huang M; Pan M
Front Immunol; 2022; 13():999763. PubMed ID: 36119069
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
